Active	Status	Sponsor type	Region	Phase	Filter
3 Active 2 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Clemens, Michael R
CLL16, NCT05197192 / 2020-004360-26: A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL	Recruiting	3	650	Europe	Obinutuzumab, Gazyva, Gazyvaro, Venetoclax, Venclexta, Venclyxto, Acalabrutinib, Calquence	German CLL Study Group, AstraZeneca	Chronic Lymphocytic Leukemia	05/26	02/27
PLATON, NCT04484636: - Platform for Analyzing Targetable Tumor Mutations (Pilot-study)	Completed	N/A	400	Europe	FoundationOne®CDx and FoundationOne®Liquid	Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Roche Pharma AG	Hepatocellular Cancer, Cholangiocarcinoma, Gallbladder Cancer, Pancreatic Cancer, Oesophageal Cancer, Stomach Cancer	08/24	08/24
PLATON, NCT05489250: The Network	Recruiting	N/A	1000	Europe		Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest	Hepatocellular Cancer, Cholangiocarcinoma, Gallbladder Cancer, Pancreatic Cancer, Oesophageal Cancer, Stomach Cancer	05/32	05/32